dc.contributor.author | Zangarini, M | |
dc.contributor.author | Berry, P | |
dc.contributor.author | Sludden, J | |
dc.contributor.author | Raynaud, FI | |
dc.contributor.author | Banerji, U | |
dc.contributor.author | Jones, P | |
dc.contributor.author | Edwards, D | |
dc.contributor.author | Veal, GJ | |
dc.date.accessioned | 2019-06-27T11:03:40Z | |
dc.date.issued | 2017-07-01 | |
dc.identifier.citation | Bioanalysis, 2017, 9 (13), pp. 1001 - 1010 | |
dc.identifier.issn | 1757-6180 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3278 | |
dc.identifier.eissn | 1757-6199 | |
dc.identifier.doi | 10.4155/bio-2017-0043 | |
dc.description.abstract | AIM: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. METHODS & RESULTS: Sample preparation involved protein precipitation with acetonitrile following addition of 13C15N-deuterated SRA737 as internal standard. A rapid and selective method was fully validated across a range of 5-20,000 ng/ml, exhibiting good sensitivity, overall precision (expressed as coefficient of variation) ≤8.0% and accuracy 96-102%. Consistently high recovery was observed, with no matrix effect and a lower limit of quantitation of 5 ng/ml. CONCLUSION: A novel method for analyzing SRA737 in human plasma has been validated and is now being utilized for quantification of SRA737 in a Phase I trial. | |
dc.format | Print-Electronic | |
dc.format.extent | 1001 - 1010 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE SCI LTD | |
dc.rights.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Humans | |
dc.subject | Protein Kinase Inhibitors | |
dc.subject | Blood Chemical Analysis | |
dc.subject | Chromatography, High Pressure Liquid | |
dc.subject | Linear Models | |
dc.subject | Tandem Mass Spectrometry | |
dc.subject | Limit of Detection | |
dc.subject | Heterocyclic Compounds, 4 or More Rings | |
dc.subject | Checkpoint Kinase 1 | |
dc.title | Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2016-04-02 | |
rioxxterms.versionofrecord | 10.4155/bio-2017-0043 | |
rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2017-07-10 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Bioanalysis | |
pubs.issue | 13 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicine Drug Development Unit (de Bono) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Pharmacology – Adaptive Therapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Medicine Drug Development Unit (de Bono) | |
pubs.publication-status | Published | |
pubs.volume | 9 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group) | |
icr.researchteam | Clinical Pharmacology – Adaptive Therapy | |
icr.researchteam | Medicine Drug Development Unit (de Bono) | |
dc.contributor.icrauthor | Raynaud, Florence | |
dc.contributor.icrauthor | Banerji, Udai | |